JP2010522141A5 - - Google Patents

Download PDF

Info

Publication number
JP2010522141A5
JP2010522141A5 JP2009546461A JP2009546461A JP2010522141A5 JP 2010522141 A5 JP2010522141 A5 JP 2010522141A5 JP 2009546461 A JP2009546461 A JP 2009546461A JP 2009546461 A JP2009546461 A JP 2009546461A JP 2010522141 A5 JP2010522141 A5 JP 2010522141A5
Authority
JP
Japan
Prior art keywords
molecule
seq
chain variable
variable region
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009546461A
Other languages
English (en)
Japanese (ja)
Other versions
JP5307030B2 (ja
JP2010522141A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/050554 external-priority patent/WO2008088983A1/en
Publication of JP2010522141A publication Critical patent/JP2010522141A/ja
Publication of JP2010522141A5 publication Critical patent/JP2010522141A5/ja
Application granted granted Critical
Publication of JP5307030B2 publication Critical patent/JP5307030B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009546461A 2007-01-18 2008-01-09 ＰＥＧ化ＡβＦＡＢ Expired - Fee Related JP5307030B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88543907P 2007-01-18 2007-01-18
US60/885,439 2007-01-18
PCT/US2008/050554 WO2008088983A1 (en) 2007-01-18 2008-01-09 PEGYLATED Aβ FAB

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013133551A Division JP5782479B2 (ja) 2007-01-18 2013-06-26 ＰＥＧ化ＡβＦＡＢ

Publications (3)

Publication Number Publication Date
JP2010522141A JP2010522141A (ja) 2010-07-01
JP2010522141A5 true JP2010522141A5 (enExample) 2011-02-10
JP5307030B2 JP5307030B2 (ja) 2013-10-02

Family

ID=39332186

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009546461A Expired - Fee Related JP5307030B2 (ja) 2007-01-18 2008-01-09 ＰＥＧ化ＡβＦＡＢ
JP2013133551A Expired - Fee Related JP5782479B2 (ja) 2007-01-18 2013-06-26 ＰＥＧ化ＡβＦＡＢ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013133551A Expired - Fee Related JP5782479B2 (ja) 2007-01-18 2013-06-26 ＰＥＧ化ＡβＦＡＢ

Country Status (26)

Country Link
US (1) US8066999B2 (enExample)
EP (2) EP2842967B1 (enExample)
JP (2) JP5307030B2 (enExample)
KR (2) KR101414847B1 (enExample)
CN (2) CN103479998B (enExample)
AR (1) AR064944A1 (enExample)
AU (1) AU2008206555B2 (enExample)
BR (1) BRPI0806715A2 (enExample)
CA (1) CA2675847C (enExample)
CL (1) CL2008000121A1 (enExample)
CY (2) CY1116157T1 (enExample)
DK (1) DK2121754T3 (enExample)
EA (1) EA020979B1 (enExample)
ES (2) ES2535641T3 (enExample)
HR (2) HRP20150237T1 (enExample)
IL (2) IL199838A (enExample)
LT (1) LT2842967T (enExample)
MX (1) MX2009007691A (enExample)
PE (1) PE20081634A1 (enExample)
PL (1) PL2121754T3 (enExample)
PT (2) PT2842967T (enExample)
RS (1) RS53948B1 (enExample)
SI (2) SI2121754T1 (enExample)
TW (1) TW200836763A (enExample)
UA (1) UA95996C2 (enExample)
WO (1) WO2008088983A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2310970B1 (en) 2008-06-20 2013-05-29 Novartis AG Methods to identify macromolecule binding and aggregation prone regions in proteins and uses therefor
CN106822891A (zh) 2008-06-20 2017-06-13 诺华公司 具有降低的聚集的免疫球蛋白
EP2437785B1 (en) * 2009-06-04 2015-02-25 Novartis AG METHODS FOR IDENTIFICATION OF SITES FOR IgG CONJUGATION
PH12012501744A1 (en) 2010-03-03 2021-08-09 Boehringer Ingelheim Int Biparatopic abeta binding polypeptides
JP6231263B2 (ja) * 2012-07-17 2017-11-15 株式会社島津製作所 アフィニティ支持体及びそれを用いた物質の捕捉方法
US10431325B2 (en) 2012-08-03 2019-10-01 Novartis Ag Methods to identify amino acid residues involved in macromolecular binding and uses therefor
WO2015036553A1 (en) * 2013-09-16 2015-03-19 Novo Nordisk Health Care Ag Thiol functionalized polymers
KR20150133576A (ko) 2014-05-20 2015-11-30 삼성전자주식회사 화학적 개질된 표적화 단백질 및 그의 이용
US10774120B2 (en) 2015-11-09 2020-09-15 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
CA3004482A1 (en) 2015-11-09 2017-05-18 Neil R. Cashman N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
KR102964291B1 (ko) 2015-11-09 2026-05-13 더 유니버시티 오브 브리티쉬 콜롬비아 아밀로이드 베타 에피토프 및 이에 대한 항체
TWI735600B (zh) 2016-07-01 2021-08-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
KR102550991B1 (ko) 2016-07-18 2023-07-04 더 유니버시티 오브 브리티쉬 콜롬비아 아밀로이드 베타에 대한 항체
JP6949102B2 (ja) 2016-08-09 2021-10-13 イーライ リリー アンド カンパニー 併用療法
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
ES2984844T3 (es) 2017-07-18 2024-10-31 Univ British Columbia Anticuerpos contra beta amiloide
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
US20210140980A1 (en) * 2018-01-04 2021-05-13 Septa Therapeutics, Inc. Septapeptides associated with neurodegeneracy
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
TW202300518A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5278049A (en) 1986-06-03 1994-01-11 Incyte Pharmaceuticals, Inc. Recombinant molecule encoding human protease nexin
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5753624A (en) 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
US5445090A (en) 1991-07-25 1995-08-29 Mim Industries, Inc. Interchangeable clamp for use in a sewing machine
US5837672A (en) 1992-07-10 1998-11-17 Athena Neurosciences, Inc. Methods and compositions for the detection of soluble β-amyloid peptide
US5766846A (en) 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
CA2115900A1 (en) 1993-02-22 1994-08-23 Gerald W. Becker Pharmaceutical screens and antibodies
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
JPH09511492A (ja) 1994-02-03 1997-11-18 ザ ピコワー インスティテュート フォア メディカル リサーチ アミロイドーシスの前進性グリコシル化終末産物仲介モジュレーション用組成物及び方法
US5668651A (en) * 1994-03-18 1997-09-16 Sharp Kabushiki Kaisha Polymer-wall LCD having liquid crystal molecules having a plane-symmetrical bend orientation
US6114133A (en) 1994-11-14 2000-09-05 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
US5688651A (en) 1994-12-16 1997-11-18 Ramot University Authority For Applied Research And Development Ltd. Prevention of protein aggregation
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5786180A (en) 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US20040121415A1 (en) * 1996-12-10 2004-06-24 King David John Monovalent antibody fragments
US6218506B1 (en) 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
US6413940B1 (en) 1997-02-07 2002-07-02 Nymox Corporation Pharmaceutically active agents that impede the formation of amyloid by impeding the genesis of DMS
US20020086847A1 (en) 1997-04-09 2002-07-04 Mindset Biopharmaceuticals (Usa) Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof
SI0994728T1 (sl) 1997-04-09 2009-02-28 Intellect Neurosciences Inc Rekombinantna protitelesa, specifična za beta-amiloidne konce, kodirana z DNA ter postopki za njihovo uporabo
US6787319B2 (en) 1997-04-16 2004-09-07 American Home Products Corp. β-amyloid peptide-binding proteins and polynucleotides encoding the same
US6227999B1 (en) 1997-07-09 2001-05-08 Transmisiones Tsp, S.A. De C.V. Method and apparatus for operating a clutch in an automated mechanical transmission
IT1293511B1 (it) 1997-07-30 1999-03-01 Gentili Ist Spa Anticorpi monoclonali catalitici ad attivita' proteasica per la lisi selettiva della componente proteica di placche e aggregati correlati
JP2001512689A (ja) 1997-08-11 2001-08-28 カイロン コーポレイション Ｔ細胞を遺伝子改変するための方法
US6448369B1 (en) 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
CA2323048C (en) 1998-03-12 2006-10-10 Shearwater Polymers, Inc. Poly(ethylene glycol) derivatives with proximal reactive groups
ES2345746T3 (es) 1998-05-21 2010-09-30 University Of Tennessee Research Foundation Metodos para la eliminacion de amiloide usando anticuerpos antiamiloide.
JP5249482B2 (ja) 1999-06-16 2013-07-31 ボストン・バイオメデイカル・リサーチ・インステイテユート インビボのβ−アミロイドレベルの免疫学的制御
ATE283285T1 (de) 1999-08-04 2004-12-15 Univ Southern California Globularer aufbau vom amyloid-beta- protein und deren verwendungen
JP2003509020A (ja) 1999-09-03 2003-03-11 ラモット・ユニバーシティ・オーソリティ・フォー・アプライド・リサーチ・アンド・インダストリアル・ディベロップメント・リミテッド プラーク形成疾患の診断、治療、予防に有用な薬剤、組成物、その使用法
US6294171B2 (en) 1999-09-14 2001-09-25 Milkhaus Laboratory, Inc. Methods for treating disease states comprising administration of low levels of antibodies
CA2394980C (en) 1999-12-22 2008-05-13 Shearwater Corporation Sterically hindered derivatives of water soluble polymers
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
EA006606B1 (ru) 2000-02-24 2006-02-24 Вашингтон Юниверсити Гуманизированное антитело и его фрагмент, взаимодействующие с бета-амилоидным пептидом, и способы их применения
US20020009445A1 (en) 2000-07-12 2002-01-24 Yansheng Du Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
WO2002021141A2 (en) 2000-09-06 2002-03-14 Aventis Pharma S.A. Methods and compositions for diseases associated with amyloidosis
US6436386B1 (en) 2000-11-14 2002-08-20 Shearwater Corporation Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
PT1416965E (pt) 2001-08-17 2008-04-01 Lilly Co Eli Método de ensaio para a doença de alzheimer
EP1429805A4 (en) 2001-08-17 2005-09-21 Lilly Co Eli USE OF ANTIBODIES WITH HIGH AFFINITY FOR A $ G (B) PEPTIDE IN THE TREATMENT OF DISEASES AND DISEASES RELATED TO A $ G (B)
EP1519740A4 (en) 2001-08-17 2005-11-09 Lilly Co Eli FASTER IMPROVEMENT OF COGNITION IN DISEASES ASSOCIATED WITH A-BETA
WO2003016466A2 (en) 2001-08-17 2003-02-27 Eli Lilly And Company ANTI-Aβ ANTIBODIES
EP1944040B1 (en) 2001-08-17 2012-08-01 Washington University Assay method for Alzheimer's disease
US7166478B2 (en) 2002-03-12 2007-01-23 Enzo Life Sciences, Inc., C/O Enzo Biochem, Inc. Labeling reagents and labeled targets, target labeling processes and other processes for using same in nucleic acid determinations and analyses
ES2318123T3 (es) 2002-04-25 2009-05-01 Eli Lilly And Company Procedimiento para tratar la ansiedad en sujetos de edad avanzada.
ATE444984T1 (de) * 2002-12-31 2009-10-15 Nektar Therapeutics Al Corp Hydrolysestabile maleimidendgruppen-enthaltende polymere
ES2344645T3 (es) * 2003-02-10 2010-09-02 Applied Molecular Evolution, Inc. Moleculas de union al abeta.
JP5087274B2 (ja) * 2003-06-30 2012-12-05 ドマンティス リミテッド ポリペプチド
WO2006040153A2 (en) * 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
US20060257396A1 (en) * 2004-12-15 2006-11-16 Jacobsen Jack S Abeta antibodies for use in improving cognition

Similar Documents

Publication Publication Date Title
HRP20161677T1 (hr) Pegilirani fab protiv amiloida beta
HRP20170110T1 (hr) Monoklonska protutijela
EA201000809A1 (ru) АНТИТЕЛА, СПЕЦИФИЧЕСКИЕ В ОТНОШЕНИИ ПРОТОФИБРИЛЛЯРНОЙ ФОРМЫ БЕЛКА β-АМИЛОИДА
RU2571204C3 (ru) Специфические связывающие агенты против в7-н1
PE20100684A1 (es) Anticuerpo anti b-4-amiloide que contiene asparagina glicosilada en la region variable de vh
ME02352B (me) PROTUTIJELA PROTIV N3pGiu-AMILOlDNOG BETA PEPTlDA l NJIHOVA UPOTREBA
CY1113630T1 (el) Αντισωματα αντι-χεπσιδινης και χρησεις εξ αυτωn
JP2013524774A5 (enExample)
CY1120014T1 (el) Αντισωματα συνδεσης πρωτοϊνιδιου και χρηση αυτων σε θεραπευτικες και διαγνωστικες μεθοδους για ασθενεια parkinson, ανοια με σωματα lewy και αλλες αλφα-συνουκλεϊνοπαθειες
JP2013525266A5 (enExample)
JP2019059786A5 (enExample)
JP2006522830A5 (enExample)
JP2013538796A5 (enExample)
JP2011528561A5 (enExample)
MX2009009226A (es) Anticuerpos recombinantes para el tratamiento de infecciones con el virus respiratorio sincitial.
JP2010539921A5 (enExample)
WO2010012004A3 (en) Monoclonal antibodies specific for pathological amyoid aggregates common to amyloids formed from proteins of differing sequence
RU2010119521A (ru) Антитела, связывающие il-4 и/или il-13, и их применение
JP2010202664A5 (enExample)
JP2010514779A5 (enExample)
JP2013535445A5 (enExample)
JP2022513331A5 (enExample)
CR20120491A (es) Proteinas de unión a antigeno especificas para el componente amiloide serico p
RU2011130522A (ru) Моноклональное антитело против hcv в качестве лекарственного средства для терапевтического лечения и профилактики инфекций hcv
JP2009529915A5 (enExample)